![]() ![]() ![]() No evidence from genome-wide data of a Khazar origin for the Ashkenazi Jews.īehar, Doron M Metspalu, Mait Baran, Yael Kopelman, Naama M Yunusbayev, Bayazit Gladstein, Ariella Tzur, Shay Sahakyan, Hovhannes Bahmanimehr, Ardeshir Yepiskoposyan, Levon Tambets, Kristina Khusnutdinova, Elza K Kushniarevich, Alena Balanovsky, Oleg Balanovsky, Elena Kovacevic, Lejla Marjanovic, Damir Mihailov, Evelin Kouvatsi, Anastasia Triantaphyllidis, Costas King, Roy J Semino, Ornella Torroni, Antonio Hammer, Michael F Metspalu, Ene Skorecki, Karl Rosset, Saharon Halperin, Eran Villems, Richard Rosenberg, Noah A These results support population testing in Ashkenazi-Jewish women with 1-4 Ashkenazi-Jewish grandparent ancestry. Population testing for BRCA mutations with varying levels of Ashkenazi-Jewish ancestry is cost-effective in the United Kingdom and the United States. Population-testing remains cost-effective in the absence of reduction in breast cancer risk from oophorectomy and at lower risk-reducing mastectomy (13%) or risk-reducing salpingo-oophorectomy (20%) rates. adjusted life-years and $100,000 per quality-adjusted life-years willingness-to-pay thresholds for all 4 Ashkenazi-Jewish grandparent scenarios, with ≥95% simulations found to be cost-effective on probabilistic sensitivity analysis. Manchanda, Ranjit Patel, Shreeya Antoniou, Antonis C Levy-Lahad, Ephrat Turnbull, Clare Evans, D Gareth Hopper, John L Macinnis, Robert J Menon, Usha Jacobs, Ian Legood, Rosa ![]() Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |